EcoDrugPlus

Histone Deacetylase 7

Ensembl ID : ENSACIG00000016655
Gene Symbol: HDAC7
1 Cross references
190 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSACIG00000012815
Gene Symbol: HDAC8
1 Cross references
206 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSACIG00000001807
Gene Symbol: HCAR1
2 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSACIG00000017445
Gene Symbol: HCN4
1 Cross references
210 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSACIG00000003525
Gene Symbol: HCN4
1 Cross references
219 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSACIG00000019544
Gene Symbol: HCRTR2
1 Cross references
201 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSACIG00000018468
Gene Symbol: IKBKB
1 Cross references
198 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSACIG00000007727
Gene Symbol: INPP5D
1 Cross references
216 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSACIG00000007680
Gene Symbol: INSRA
1 Cross references
230 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSACIG00000006754
Gene Symbol: INSRB
1 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSACIG00000023462
Gene Symbol: IGF1RA
1 Cross references
206 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSACIG00000007009
Gene Symbol: IGF1RB
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).